Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

University of Notre Dame

https://www.nd.edu/

Latest From University of Notre Dame

Asia Deal Watch: Qpex Partners Its Experimental Antibiotics With Brii In Greater China

Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.

Deals Asia Pacific

Deals Shaping The Medical Industry, April 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.

Deals BioPharmaceutical

Recent Tech Transfer Deals, October 2012

START-UP’s monthly update on technology transfer deals—licensing agreements between companies and universities or other research institutions—in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.

BioPharmaceutical Medical Device

Eli Lilly's Open Source Approach To Early Stage Research

Eli Lilly, which like many big pharmas faces patent expiries and an uncertain late-stage pipeline, has worked to improve ties with the venture and academic communities to help spur access to early-stage and less expensive assets. Since 2009 it has operated a web portal that allows outside researchers to submit compounds for interrogation using Eli Lilly’s drug-discovery assays.

See All

Company Information

  • Industry
  • Academic and Research Institutions
UsernamePublicRestriction

Register